Selexys Pharmaceuticals Corporation and Cytovance Biologics Sign Deal for the Process Development and cGMP Manufacture of Selexys Pharmaceutical Corporation’s Product HPL1 Monoclonal Antibody (Mab)

OKLAHOMA CITY--(BUSINESS WIRE)--Cytovance® Biologics LLC, a biopharmaceutical contract manufacturing company specializing in mammalian cell culture, today announced the signing of a full service process development and manufacturing collaboration with Selexys Pharmaceutical Corporation.